Andrew Lees Named to The Power List 2016
Dr. Andrew Lees, founder and Chief Scientific Officer of Fina Biosolutions, has been named to The Power List 2016 – the Top 100 most influential people in the world of…
Now Available: A Comprehensive Review of the Uses of Antibody-dextran Conjugates by Dr. Snapper
This technical paper by presents an overview of the development and applications of antibody dextran conjugates. Fina Biosolutions provides anti-IgD and anti-IgM dextrans (mouse and human) as well as other…
Fina CEO Andrew Lees Honored by Harvey Mudd College
An esteemed research scientist and world-recognized leader in vaccine development, Andrew Lees founded Fina BioSolutions, a company committed to eliminating vaccine-preventable deaths of infants and children in emerging-market countries. With…
BIO2015 Interview with Fina Biosolutions
SNNLive spoke with Andrew Lees, Ph.D., Scientific Director of Fina Biosolutions LLC at the BioMaryland Booth at BIO International 2015 in Philadelphia, PA.
Andrew Lees to Give Keynote Presentation at 10th Global Summit and Expo on Vaccines & Vaccination in Rome
Dr. Lees will discuss the challenges of developing and manufacturing affordable conjugate vaccines. He will review how efficient conjugation chemistry and affordable carrier protein can help reduce manufacturing costs.
Characterization of Fina Biosolutions’ Amino-Dextran
Comparison with Other Commercially Available Amino Dextrans The performance of AmDex in any application depends on its homogeneity and purity. The low percent dextran found in competitor AmDex means that…